Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

AstraZeneca

37 clinical trials · 37 recruiting · INDUSTRY

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by AstraZeneca

RECRUITINGPhase 3NCT06380751

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in...

The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2,...

Sponsor: AstraZenecaEnrolling: 50020 locations
Advanced Breast Cancer
RECRUITINGPhase 3NCT06350097

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced...

The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas...

Sponsor: AstraZenecaEnrolling: 58220 locations
Non-small Cell Lung Cancer
RECRUITINGNCT06491862

RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based...

The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a/m non-squamous...

Sponsor: AstraZenecaEnrolling: 25011 locations
Non-squamous Non-Small Cell Lung Cancer
RECRUITINGNCT07052578

Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate...

A multicentre observational study on treatment patterns and ctDNA HRR evaluation in aggressive high-volume metastatic hormone-sensitive prostate cancer in Russian Federation

Sponsor: AstraZenecaEnrolling: 40018 locations
Prostate Cancer
RECRUITINGPhase 3NCT07218809

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian...

The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade,...

Sponsor: AstraZenecaEnrolling: 110020 locations
Epithelial Ovarian Cancer
RECRUITINGPhase 2NCT05775159

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced...

GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with...

Sponsor: AstraZenecaEnrolling: 29420 locations
Hepatocellular CarcinomaBiliary Tract Cancer
RECRUITINGPhase 1 / Phase 2NCT06795022

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in...

Sponsor: AstraZenecaEnrolling: 30420 locations
Hepatocellular Carcinoma
RECRUITINGPhase 3NCT06960577

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder...

The Phase IIIb NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with investigator-selected...

Sponsor: AstraZenecaEnrolling: 15020 locations
Urinary Bladder NeoplasmsImmune Checkpoint InhibitorsMethotrexate+4
RECRUITINGPhase 3NCT06097728

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the...

Sponsor: AstraZenecaEnrolling: 82520 locations
Unresectable Pleural Mesothelioma
RECRUITINGPhase 2NCT06535607

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic...

eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.

Sponsor: AstraZenecaEnrolling: 25720 locations
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)+2
RECRUITINGPhase 1NCT07295847

A Study of AZD0120 in Autoimmune Diseases

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult...

Sponsor: AstraZenecaEnrolling: 2718 locations
Systemic SclerosisIdiopathic Inflammatory MyopathiesRheumatoid Arthritis
RECRUITINGNCT06465810

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe...

Sponsor: AstraZenecaEnrolling: 185020 locations
Transthyretin AmyloidosisATTR-CMATTRv-PN+3
RECRUITINGPhase 3NCT06677060

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined...

Sponsor: AstraZenecaEnrolling: 1130020 locations
Heart Failure
RECRUITINGPhase 1NCT07241104

A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy

The purpose of the study is to assess the safety, tolerability and the pharmacokinetics (PK) of AZD4063 after single and multiple dose administration in participants with...

Sponsor: AstraZenecaEnrolling: 314 locations
Dilated Cardiomyopathy
RECRUITINGPhase 4NCT06594068

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users (PRIMULA Lac) is a Post Marketing Requirements (PMR) study designed to fulfill the...

Sponsor: AstraZenecaEnrolling: 161 location
Systemic Lupus Erythematosus
RECRUITINGNCT07000110

Anifrolumab Malignancy and Serious Infections Study

This is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive...

Sponsor: AstraZenecaEnrolling: 31954 locations
Systemic Lupus Erythematosus
RECRUITINGNCT06659029

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a prospective, observational cohort study designed to evaluate the...

Sponsor: AstraZenecaEnrolling: 4421 location
Systemic Lupus Erythematosus
RECRUITINGNCT06909253

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.

Sponsor: AstraZenecaEnrolling: 5014 locations
Myasthenia Gravis, Generalized
RECRUITINGNCT07247279

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

This is a multicenter, non-interventional, retrospective-prospective, single-arm observational study designed to describe real-world treatment approaches and clinical outcomes...

Sponsor: AstraZenecaEnrolling: 4503 locations
Rare DiseasesGeneralized Myasthenia Gravis (gMG)
RECRUITINGPhase 1NCT07316608

A Phase I, Open-label, Crossover Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of...

The purpose of this study is to assess how well laroprovstat and rosuvastatin combined in a single tablet to be taken by mouth works compared with laroprovstat and rosuvastatin...

Sponsor: AstraZenecaEnrolling: 442 locations
Healthy Participants
RECRUITINGPhase 3NCT06023589

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old...

To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one...

Sponsor: AstraZenecaEnrolling: 23120 locations
Asthma
RECRUITINGPhase 3NCT07363642

Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab

This study aims to explore the potential for Tezepelumab-treated severe asthmatic patients to effectively and safely reduce their background maintenance medication while...

Sponsor: AstraZenecaEnrolling: 40020 locations
Severe Asthma
RECRUITINGNCT06472310

Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)

This study is an observational multicenter cross-sectional study. Planned study population consists of 5 000 adult patients with uncontrolled SA receiving treatment according to...

Sponsor: AstraZenecaEnrolling: 500020 locations
Severe Asthma
RECRUITINGPhase 1NCT07433569

A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With...

The purpose of this study is to assess the pharmacokinetics (PK) and safety of symbicort aerosphere and symbicort pressurized metered dose inhaler (pMDI) in participants with...

Sponsor: AstraZenecaEnrolling: 126 locations
Asthma
RECRUITINGNCT07245576

Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis

Current diagnostic methods for asthma and chronic obstructive pulmonary disease mostly depend on pulmonary function tests, especially spirometry. While spirometry is a...

Sponsor: AstraZenecaEnrolling: 60012 locations
AsthmaCOPD
RECRUITINGNCT06422078

A Non-interventional, Prospective Study With Benralizumab

This is a prospective, non-interventional, single-arm, multicenter study to investigate asthma control, and health-related quality of life (HRQL), lung function and asthma...

Sponsor: AstraZenecaEnrolling: 30020 locations
Asthma, Bronchial
RECRUITINGNCT06862206

This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China...

The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above,...

Sponsor: AstraZenecaEnrolling: 100020 locations
Chronic Obstructive Pulmonary Disease
RECRUITINGPhase 3NCT06283966

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on...

This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg...

Sponsor: AstraZenecaEnrolling: 500020 locations
COPD (Chronic Obstructive Pulmonary Disease)
RECRUITINGNCT06780046

Study That Will Evaluate the Brazilian Population With COPD.

Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the...

Sponsor: AstraZenecaEnrolling: 69310 locations
COPD (Chronic Obstructive Pulmonary Disease)
RECRUITINGPhase 3NCT06878261

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD...

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very...

Sponsor: AstraZenecaEnrolling: 99020 locations
Chronic Obstructive Pulmonary Disease (COPD)

Showing 30 of 37 trials.